OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET,
December 21, 2009
BOTHELL, WA and
A live webcast will be available through the Investor Relations page of the OncoGenex Web site at http://ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 888-747-4649 (U.S. &
About OncoGenex Pharmaceuticals
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase II clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase I clinical development; SN2310 has completed a Phase I clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.
For further information: OncoGenex Contact: Scott Cormack, President & CEO, (604) 630-5400, [email protected]; Media and Investor Contact: Jason Spark, Porter Novelli Life Sciences, (619) 849-6005, [email protected]
Share this article